Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Adlai NortyeANL +3.40%8 3-Year EBITDA Growth Rate is 12.60% as of Jun. 2026, which is 121% above its 10-year median of 5.70. GuruFocus rates ANL with a GF Score™ of 8/100. The stock has 8 warning signs investors should review. Among 1,127 Biotechnology companies, Adlai Nortye ranks worse than 52.44% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 12.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Adlai Nortye was 12.60% per year. The lowest was -1.20% per year. And the median was 5.70% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Adlai Nortye 3-Year EBITDA Growth Rate Related Terms
ANL vs TBPH, ACRS, ATTO: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Adlai Nortye's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adlai Nortye 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adlai Nortye's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Adlai Nortye's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 12.60% mean?
Adlai Nortye (ANL) has a 3-Year EBITDA Growth Rate of 12.60% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Adlai Nortye and its competitors. This is 121% above median its historical median of 5.70. According to the industry distribution chart, Adlai Nortye ranks #591 out of 1127 companies in the Biotechnology industry, placing it in the top 52.4%.
Is Adlai Nortye's 3-Year EBITDA Growth Rate too high?
Adlai Nortye's current 3-Year EBITDA Growth Rate of 12.60% is 121% above median its 10-year median of 5.70. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.60. Adlai Nortye's value of 12.60% is 13.7% below this industry median. Based on the distribution chart, Adlai Nortye ranks #591 out of 1127 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Adlai Nortye has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Adlai Nortye's 3-Year EBITDA Growth Rate compare to TBPH and ACRS?
According to the Biotechnology industry distribution chart, Adlai Nortye ranks #591 out of 1127 companies for 3-Year EBITDA Growth Rate. This places Adlai Nortye in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.60. Adlai Nortye's value of 12.60% is 13.7% below this benchmark. While the company's 10-year median is 5.70 vs. the industry median of 14.60, Adlai Nortye has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.60, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Adlai Nortye's current 3-Year EBITDA Growth Rate of 12.60% is 13.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Adlai Nortye and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adlai Nortye's current 3-Year EBITDA Growth Rate is 12.60%, which is 121% above median its own 10-year median of 5.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adlai Nortye stock overvalued right now?
Adlai Nortye (ANL) has a current 3-Year EBITDA Growth Rate of 12.60%. The current 3-Year EBITDA Growth Rate is 12.60%, which is 121% above median its 10-year median of 5.70 and 13.7% below the Biotechnology industry median of 14.60. Adlai Nortye's overall GF Score™ is 8/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Adlai Nortye (ANL), the current 3-Year EBITDA Growth Rate is 12.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.
8GF Score
Get the complete analysis for ANL
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANL has been successfully added to your 
